Pharmaceuticals

Dr. S. Leigh Verbois, a veteran FDA regulator, takes the helm at Rx-360, signaling a new, tech-driven era for securing global pharmaceutical supply chains.

The U.S. Fish and Wildlife Service again denied a petition to list long-tailed macaques as endangered, a move hailed by researchers but decried by activists.

Seattle's Sound Pharma completes key Phase 3 enrollment for SPI-1005, putting the first-ever approved drug for debilitating Meniere's disease on the horizon.

A C$11.5 million deal for a company you've never heard of is set to accelerate the takeover of independent pharmacies. Is it a lifeline or the end of an era?

A small biotech is raising millions with a high-risk funding plan to launch a BOTOX alternative. Can it survive long enough to disrupt a pharma titan?

Ironwood Pharmaceuticals appoints a veteran CMO and launches a key Phase 3 trial, signaling a strategic pivot beyond its blockbuster to conquer rare diseases.

Kura Oncology's upcoming kidney cancer data is just the tip of the iceberg. A closer look reveals a strategic play to make darlifarnib a universal partner drug.

A U.S.-China partnership is testing a drug that could replace cataract surgery. The ZOC2017217 eye drop aims to reverse vision loss for millions.

With a fresh $150M, Mighty Therapeutics is set to expand its groundbreaking mitochondrial drugs from rare diseases to major conditions like Parkinson's.

Landmark Phase 3 data for HBI-8000 not only offers new hope for melanoma patients but validates a powerful "China-to-global" drug development strategy.

Atrium Therapeutics' clinical trial for a rare cardiomyopathy isn't just a milestone; it's a strategic maneuver signaling the arrival of precision RNA therapies in cardiology.

A new watchdog emerges as millions use unapproved GLP-1 drugs, many believing they're FDA-approved. How a shortage solution became a risky shadow market.

Elevara Medicines taps biotech veteran Dr. Mai-Britt Zocca to lead its charge against rheumatoid arthritis with a novel drug and $70M in backing.

Eupraxia Pharmaceuticals is overhauling its leadership and relocating to major biotech hubs, betting it all on its late-stage pipeline and a pivotal trial.

Milla Pharmaceuticals' new FDA approval for a vital acidosis drug offers hope for hospitals battling chronic shortages and marks a key strategic win for parent A.forall.

How one company's relentless focus on data-driven quality, validated by a prestigious URAC 'Pioneer' award, is redefining safety standards in specialized medicine.

With a new CMO, $50M in fresh capital, and pivotal trials on the horizon, Cue Biopharma makes a strategic bet on an immunology veteran to guide its future.

After an initial rejection, Sydnexis's pediatric myopia drug gets a crucial FDA hearing, raising hopes for the first approved U.S. pharmaceutical treatment.

Alto Neuroscience's $100M raise fuels its quest to treat resistant depression. It's a high-stakes play on a biomarker-driven approach in a challenging field.

Delonix Bioworks is running parallel trials in China and Australia for its MenB vaccine, a strategic gambit that could disrupt a billion-dollar market.